{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:14:51Z","timestamp":1776377691051,"version":"3.51.2"},"reference-count":123,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.1080\/17474086.2023.2276206","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:59:37Z","timestamp":1698314377000},"page":"919-932","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"first","affiliation":[{"name":"Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-9062","authenticated-orcid":false,"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[{"name":"Vascular Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W","family":"Pipe","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Pathology, University of Michigan Medical School, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,11,12]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12108"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13449"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12375"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.09.008"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221085202"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14675"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S139851"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2349.2349"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14072"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15444"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S63265"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06657.x"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24218"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3402\/qhw.v10.28915"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718791933"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000540"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-820720"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.069"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1564032"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14778"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-687434"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13647"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13251"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_3_5_34_1","unstructured":"BioMarin. ROCTAVIAN - Summary of product characteristics [Accessed Jun 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roctavian-epar-product-information_en.pdf"},{"key":"e_1_3_5_35_1","unstructured":"BioMarin. ROCTAVIAN - Prescribing Information [Accessed Oct 2023]. Available from: https:\/\/www.fda.gov\/media\/169937\/download?attachment"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-03-0179"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12878"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_3_5_40_1","unstructured":"World Federation of Hemophilia Online Registry of Clotting Factor Concentrates 2023 [Apr 2023]. Available from: https:\/\/wfh.org\/article\/wfh-online-registry-of-clotting-factor-concentrates\/"},{"key":"e_1_3_5_41_1","unstructured":"Pfizer. Prescribing information - BeneFIX [Accessed Feb 2023]. Available from: https:\/\/www.fda.gov\/media\/73556\/download"},{"key":"e_1_3_5_42_1","unstructured":"Pfizer. BeneFIX - Summary of product characteristics [Accessed Feb 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benefix-epar-product-information_en.pdf"},{"key":"e_1_3_5_43_1","unstructured":"Takeda. Prescribing information - RIXUBIS [Accessed Feb 2023]. Available from: https:\/\/www.fda.gov\/media\/86123\/download"},{"key":"e_1_3_5_44_1","unstructured":"Takeda. RIXUBIS - Summary of product characteristics [Accessed Feb 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rixubis-epar-product-information_en.pdf"},{"key":"e_1_3_5_45_1","unstructured":"CSL Behring. IDELVION - Summary of product characteristics [Accessed Feb 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idelvion-epar-product-information_en.pdf"},{"key":"e_1_3_5_46_1","unstructured":"CSL Behring. Prescribing information - IDELVION [Accessed Feb 2023]. Available from: https:\/\/www.fda.gov\/media\/96526\/download"},{"key":"e_1_3_5_47_1","unstructured":"Sobi. Prescribing Information - ALPROLIX [Accessed Feb 2023]. Available from: https:\/\/www.fda.gov\/media\/88119\/download"},{"key":"e_1_3_5_48_1","unstructured":"Sobi. ALPROLIX - Summary of product characteristics [Accessed Feb 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alprolix-epar-product-information_en.pdf"},{"key":"e_1_3_5_49_1","unstructured":"Novo Nordisk. REFIXIA - Summary of product characteristics [Accessed Feb 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/refixia-epar-product-information_en.pdf"},{"key":"e_1_3_5_50_1","unstructured":"Novo Nordisk. Prescribing information - REBINYN [Accessed Feb 2023]. Available from: https:\/\/www.fda.gov\/media\/105491\/download"},{"key":"e_1_3_5_51_1","unstructured":"CSL Behring. Prescribing information - HEMGENIX [Accessed Jan 2023]. Available from: https:\/\/www.fda.gov\/media\/163467\/download"},{"key":"e_1_3_5_52_1","unstructured":"CSL Behring. HEMGENIX - Summary of product characteristics 2023 [Mar 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemgenix-epar-product-information_en.pdf"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124091"},{"key":"e_1_3_5_54_1","unstructured":"ClinicalTrials.gov; NCT03861273 [February 2023]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03861273"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"key":"e_1_3_5_56_1","unstructured":"ClinicalTrials.gov; NCT03754790[Accessed Jun 2023]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03754790"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_3_5_58_1","unstructured":"ClinicalTrials.gov; NCT04083781 [Accessed Jun 2023]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04083781"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_3_5_60_1","unstructured":"ClinicalTrials.gov; NCT03938792 [Accessed Jun 2023]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03938792"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159631"},{"key":"e_1_3_5_62_1","unstructured":"ClinicalTrials.gov; NCT05789524 [Accessed Jun 2023]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05789524"},{"key":"e_1_3_5_63_1","unstructured":"Medicines and Healthcare products regulatory Agency. Orphan registered medicinal products: HEMGENIX 2023 [Mar 2023]. Available from: https:\/\/www.gov.uk\/government\/publications\/orphan-registered-medicinal-products\/orphan-register#hemgenix-1-x-1013-genome-copiesml-concentrate-for-solution-for-infusion"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205"},{"key":"e_1_3_5_65_1","unstructured":"Pfizer. Pfizer and sangamo therapeutics announce Phase 3 trial of investigational gene therapy for hemophilia a has re-opened recruitment 2022. Available from: https:\/\/www.pfizer.com\/news\/announcements\/pfizer-and-sangamo-therapeutics-announce-phase-3-trial-investigational-gene"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119913"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008886"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211075"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118334"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804419"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904377"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.09.005"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000811"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.007"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.007"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.05.009"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166810"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.031"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017913"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3229"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.037"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009876"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.4081\/btvb.2023.70"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166135"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.287"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003777"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14391"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148651"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.5.731"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.2450\/2018.0272-17"},{"key":"e_1_3_5_99_1","unstructured":"National Hemophilia Foundation. Sanofi revises fitusiran dosing regimen to mitigate risk of vascular thrombosis 2021 [06 Jun 2023]. Available from: https:\/\/www.hemophilia.org\/news\/sanofi-revises-fitusiran-dosing-regimen-to-mitigate-risk-of-vascular-thrombosis"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.5482\/20170004"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007435"},{"issue":"2","key":"e_1_3_5_102_1","first-page":"90","article-title":"Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B","volume":"5","author":"Miesbach W","year":"2021","unstructured":"Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B. Res Pract Thromb Haemost. 2021;5(Suppl 2): 90.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158903"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016359"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148661"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002867"},{"issue":"1","key":"e_1_3_5_108_1","first-page":"43","article-title":"Analysis of elevated alanine transaminase in HOPE-B, a Phase 3 recombinant adeno-associated viral 5 gene therapy trial in people with haemophilia B (PO040)","volume":"29","author":"Astermark J","year":"2023","unstructured":"Astermark J, Lucas S, Chen L, et al. Analysis of elevated alanine transaminase in HOPE-B, a Phase 3 recombinant adeno-associated viral 5 gene therapy trial in people with haemophilia B (PO040). Haemophilia. 2023;29(S1):43.","journal-title":"Haemophilia"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13769"},{"key":"e_1_3_5_110_1","unstructured":"BioMarin. BioMarin Announces durable Hemostatic efficacy maintained over 6 years in Ongoing Phase 1\/2 study of valoctocogene roxaparvovec investigational gene therapy for hemophilia a 2022. Available from: https:\/\/investors.biomarin.com\/2022-05-31-BioMarin-Announces-Durable-Hemostatic-Efficacy-Maintained-Over-6-years-in-Ongoing-Phase-1-2-Study-of-Valoctocogene-Roxaparvovec -Investigational-Gene-Therapy-for-Hemophilia-A"},{"key":"e_1_3_5_111_1","first-page":"8","author":"United States Securities and Exchange Commission","year":"2022","unstructured":"United States Securities and Exchange Commission . BioMarin Pharamceuticals Inc Form. 2022;8\u2013K.","journal-title":"BioMarin Pharamceuticals Inc Form"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.014"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.11.026"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14015"},{"key":"e_1_3_5_115_1","unstructured":"Food and Drug Administration. Long term follow-up after administration of human gene therapy products 2020. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products"},{"key":"e_1_3_5_116_1","unstructured":"World Federation of Hemophilia Gene Therapy Registry 2022. Available from: https:\/\/elearning.wfh.org\/resource\/the-world-federation-of-hemophilia-gene-therapy-registry-informational-webinar\/"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S406894"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02256-2"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14383"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14190"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14378"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14420"},{"key":"e_1_3_5_123_1","unstructured":"EAHAD \u2013 EHC Statement on Gene Therapies Hub-and-Spoke Model [Apr 2023]. Available from: https:\/\/www.eahad.org\/eahad-ehc-statement-on-promoting-hub-and-spoke-model-using-gene-therapies\/"},{"key":"e_1_3_5_124_1","unstructured":"European Medicines Agency. Summary of opinion: initial authorisation HEMGENIX 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-hemgenix_en.pdf"},{"issue":"1","key":"e_1_3_5_125_1","first-page":"24","article-title":"Durability of response after long-term follow-up in the Phase 1\/2 study of AMT-060, and Phase 2b and 3 studies of etranacogene dezaparvovec in haemophilia B","volume":"29","author":"Miesbach W","year":"2023","unstructured":"Miesbach W, Recht M, Key NS, et al. Durability of response after long-term follow-up in the Phase 1\/2 study of AMT-060, and Phase 2b and 3 studies of etranacogene dezaparvovec in haemophilia B. Haemophilia. 2023;29(S1):24\u2013202.","journal-title":"Haemophilia"},{"key":"e_1_3_5_126_1","unstructured":"Institute for Clinical and Economic Review. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: final Policy Recommendations [Accessed Jan 2023]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2022\/12\/ICER-Hemophilia-Policy-Recommendations-122222.pdf"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2023.2276206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:21:27Z","timestamp":1727184087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2023.2276206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,12]]},"references-count":123,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,2]]}},"alternative-id":["10.1080\/17474086.2023.2276206"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2023.2276206","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}